Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib in Refractory/Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
NCT00039585Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2002
- Primary completion
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in ovarian epithelial cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by National Cancer Institute. Primary endpoint: Clinical response in patients with epithelial ovarian cancer. Started May 2002; status: completed.
02
Drugs
03
Conditions
ovarian epithelial cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00039585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00039585.